Visugromab

Phase 2Monoclonal antibody

CCatalYm GmbH

Visugromab is one of 91 biologic programs targeting Cachexia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CachexiaActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Bladder CancerActive, not recruiting

Metastatic Non-Squamous Non Small Cell Lung CancerRecruiting

CachexiaPhase 2/Phase 3

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Metastatic Non-Squamous Non Small Cell Lung CancerPhase 2

Recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Visugromab

CCatalYm GmbH

Phase 2

6 2

Ibrance

Pfizer

Preclinical

1 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Hepsera

Coreg

2 6

Doptelet

AAkarx

Preclinical

1 7

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 8

Vermox

WWim Janssens

Preclinical

1 9

Opdivo

Bristol-Myers Squibb

Preclinical

2 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Bladder Cancer

NCT06059547

Q2 2030

Phase 1/2Active, not recruiting

Advanced Cancer

NCT04725474

Q4 2030

Phase 2/3Recruiting

Cachexia

NCT07112196

Q1 2031

Phase 2Recruiting

Metastatic Non-Squamous Non Small Cell Lung Cancer

NCT07098988

Clinical

Trials by Indication[1]

Cachexia1 trial

Visugromab in Cachexia International Trial

Recruiting·CCatalYm GmbH·Phase 2/3·NCT07112196·518 enrolled

Advanced Cancer1 trial

First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)

Active, not recruiting·CCatalYm GmbH·Phase 1/2·NCT04725474·263 enrolled

Bladder Cancer1 trial

Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting·CCatalYm GmbH·Phase 2·NCT06059547·31 enrolled

Metastatic NSCLC1 trial

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Recruiting·CCatalYm GmbH·Phase 2·NCT07246863·131 enrolled

Metastatic Non-squamous Non Small Cell Lung Cancer1 trial

A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)

Recruiting·CCatalYm GmbH·Phase 2·NCT07098988·107 enrolled

1 more indication

Metastatic Hepatocellular Carcinoma1 trial

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

Recruiting·CCatalYm GmbH·Phase 2·NCT07219459·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Visugromab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Visugromab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Visugromab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CatalYm GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: CCatalYm GmbH

Visugromab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2030

Q4 2030

Q1 2031

Trials by Indication[1]

Cachexia1 trial

Advanced Cancer1 trial

Bladder Cancer1 trial

Metastatic NSCLC1 trial

Metastatic Non-squamous Non Small Cell Lung Cancer1 trial

Metastatic Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News